Gastric Cancer & ImmunotherapyMelanomaPublic · Grade 3AFounded 1976PKU Affiliated
Peking University Cancer Hospital China's deepest gastric cancer expertise
A dedicated cancer hospital affiliated with Peking University, internationally recognised for gastric cancer research, melanoma treatment in Asian patients, and immunotherapy trials that have changed the way oncologists globally approach these cancers. For patients with gastric cancer, colorectal cancer, or advanced melanoma, PKU Cancer Hospital offers access to physicians who are active at the frontiers of the research. China Care coordinates international patient access via the VIP Oncology Service.
52 Fucheng Road, Haidian District, Beijing — ~40 min from Capital Airport
Quick Facts
Payment
RMB only — paid directly to hospital
Consultation
In-person only at VIP Oncology Service
Advance booking
1–2 weeks minimum
Language
English (VIP dept) + bilingual escort
Type
Public hospital · Grade 3A · PKU Affiliated
#1 China
Gastric cancer research ranking
Immunotherapy
Research shaping global guidelines
PKU
Peking University affiliated
Haidian
Academic district, Beijing
About the Hospital
Where the Research Happens That Determines What Oncologists Worldwide Do Next
Peking University Cancer Hospital (北京大学肿瘤医院) is one of China's premier specialist oncology institutions, founded in 1976 and affiliated with Peking University. Its international reputation is built primarily on two areas: gastric cancer — where it holds China's highest research ranking — and melanoma, where it runs the most sophisticated programme in Asia for patients with the mutation profiles most commonly found in Asian populations.
The hospital's immunotherapy research has produced findings that have directly shaped treatment guidelines globally. Its oncologists author the clinical protocols not just for domestic use but for international oncology bodies. For patients seeking cancer treatment in China at an institution at the research frontier, PKU Cancer Hospital represents the highest tier of academic oncology.
The hospital treats the full range of gastrointestinal and gynaecological malignancies alongside its specialist programmes. Colorectal cancer, gastroesophageal cancer, and gynaecological oncology all benefit from the proximity to the gastric cancer and immunotherapy programmes — shared protocols, integrated trial portfolios, and the cross-fertilisation of research insights between departments.
"For gastric cancer specifically, this is where the research happens that determines what oncologists worldwide do next."
Why Patients Choose PKU Cancer Hospital
Three reasons international patients choose PKU Cancer Hospital
Deepest Gastric Cancer Expertise in China
PKU Cancer Hospital holds China's highest ranking for gastric cancer research. Its oncologists have authored the clinical guidelines that govern how gastric cancer is treated domestically and have contributed landmark publications that changed international practice. For patients with gastric cancer, gastroesophageal junction cancer, or related GI malignancies, no institution in China has deeper disease-specific expertise.
Immunotherapy Research That Shapes Global Guidelines
The immunotherapy programme at PKU Cancer Hospital has generated data that has informed both Chinese and international treatment guidelines. Its clinical trial portfolio covers novel checkpoint inhibitor combinations and biomarker-driven patient selection approaches. Patients whose tumours have not responded to standard immunotherapy regimens may qualify for trials investigating next-generation approaches not yet available elsewhere.
Specialist Melanoma Programme for Asian Mutation Profiles
Melanoma in Asian patients commonly presents with acral lentiginous or mucosal subtypes with distinct mutation profiles — often KIT or BRAF non-V600 — compared to UV-driven melanoma in Western populations. PKU Cancer Hospital's melanoma programme has extensive experience with these Asian-specific subtypes and the targeted and immunotherapy regimens appropriate for them. Patients who have received suboptimal treatment based on protocols designed for Western melanoma cohorts often find more appropriate options here.
Clinical Departments
Oncology Specialties Available to International Patients
PKU Cancer Hospital specialises in gastrointestinal oncology, immunotherapy, and melanoma, with strong complementary programmes in colorectal and gynaecological cancers. The following departments are most frequently accessed by international patients coordinated through China Care.
Primary Focus
Gastric Cancer
China's leading gastric cancer research and clinical centre. Covers early-stage to metastatic gastric cancer and gastroesophageal junction tumours. Biomarker-driven treatment selection using HER2, PD-L1, MMR status, and molecular profiling. High surgical volume with complete D2 lymph node dissection expertise.
Gastric CancerGEJ TumoursD2 GastrectomyHER2+
Primary Focus
Immunotherapy
One of China's leading immunotherapy research programmes. Clinical trial portfolio covering novel checkpoint inhibitor combinations, bispecific antibodies, and biomarker-driven patient selection. Active Phase I–III studies across multiple tumour types. International patients may qualify for trials involving agents not yet approved elsewhere.
Asia's leading specialist melanoma centre for acral lentiginous and mucosal subtypes. Extensive experience with KIT, NF1, and BRAF non-V600 mutations common in Asian patients. Personalised treatment protocols based on genetic profiling rather than protocols designed for Western UV-driven melanoma cohorts.
Acral LentiginousMucosal MelanomaKIT Targeted
Also Available
Colorectal Cancer
High-volume colorectal oncology programme including surgical, medical, and radiation approaches. Minimally invasive laparoscopic and robotic resection where appropriate. Microsatellite instability (MSI) and RAS/BRAF testing integrated into treatment planning for all metastatic cases.
LaparoscopicRobotic ResectionMSI Testing
Also Available
Gynaecological Oncology
Specialist department covering cervical, endometrial, and ovarian cancers. Fertility-sparing surgery where clinically appropriate. BRCA and homologous recombination deficiency (HRD) testing available to guide PARP inhibitor treatment selection in ovarian cancer.
Cervical & OvarianBRCA / HRDPARP Inhibitors
Access via China Care
Not sure which department is right for your case?
Submit your records to China Care. We review your pathology and staging, identify the most appropriate department at PKU Cancer Hospital, and conduct a proxy consultation with the relevant specialist before you travel.
China Care coordinates the intake process for international oncology patients, from initial records submission to arrival support in Beijing.
Step 1
Submit Oncology Records to China Care
Send your pathology reports including biopsy results, IHC panel, and molecular profiling where available — especially HER2, PD-L1, MMR/MSI, RAS/BRAF status for GI cancers; KIT, BRAF, and NRAS status for melanoma. Include staging investigations, imaging, and full prior treatment history. China Care prepares a structured bilingual case summary within 1–2 working days.
full pathology & molecular profiling · 1–2 days
Step 2
China Care Conducts a Proxy Consultation on Your Behalf
China Care attends PKU Cancer Hospital in person and consults with the relevant oncology specialist on your behalf — before you travel. The specialist reviews your case summary, gives initial clinical direction, and flags whether your case may qualify for any active clinical trials. China Care reports the outcome back to you with real-time voice interpretation.
This service is charged at a fixed fee covering hospital registration, the proxy consultation, and voice interpretation. Already in China? Skip this step — China Care can arrange direct escort and interpretation for your own visit instead.
proxy consultation · fixed fee · results same day
Step 3
Travel to Beijing for Your In-Person Consultation
With the specialist's initial direction confirmed, you travel to Beijing for your own in-person consultation at the VIP Oncology Service. The specialist issues a formal treatment plan and cost estimate — this step cannot be completed remotely at a public hospital. Cases under consideration for clinical trial enrolment may receive an additional eligibility review. China Care's bilingual coordinator accompanies you throughout.
in-person consultation · treatment plan & cost estimate issued
Step 4
Admission & Treatment
Admission is arranged through the VIP Oncology Service once you confirm treatment. China Care's coordinator remains available throughout your stay for language support and coordination with hospital administration.
All treatment fees are paid directly to the hospital in Chinese yuan (RMB). PKU Cancer Hospital does not accept international credit cards for inpatient treatment. A deposit is required at admission; the balance is settled before discharge. China Care does not collect or handle medical payments.
VIP Oncology Service · RMB payment direct to hospital
Step 5
Discharge and Follow-Up
Full bilingual discharge documentation is provided at discharge. An English-language summary is prepared for your home oncologist. For patients enrolled in clinical trials, follow-up schedules and reporting protocols are confirmed at discharge. China Care provides post-discharge support for any queries.
bilingual documentation · post-discharge support
Proxy consultation (fixed fee)Bilingual case coordinationClinical trial eligibility reviewIn-person escort & interpretationRMB payment direct to hospitalBilingual discharge documents
Before You Travel
What international patients need to know
Payment
RMB only
All fees paid directly to hospital in Chinese yuan. No international credit cards. Deposit required at admission.
Advance booking
1–2 weeks minimum
All appointments booked through China Care before you travel. Walk-in not available for international patients.
Consultation type
In-person only
Public hospital. All specialist consultations take place in person at the VIP Oncology Service. Remote consultation not available.
Language
English + bilingual escort
VIP Oncology Service physicians speak English. Ward staff: Mandarin. China Care provides escort and interpretation throughout.
From airport
~40 min taxi
From Beijing Capital Airport to Haidian District. Metro Line 10 (Lianhuachi) or Line 6 (Haidian Wuluju) nearby.
Hospital type
Public · Grade 3A
Peking University affiliated. Treatment costs quoted directly by hospital — zero markup from China Care.
Common Questions
What patients ask about PKU Cancer Hospital
Why is PKU Cancer Hospital specifically recommended for gastric cancer?
PKU Cancer Hospital holds China's highest research ranking for gastric cancer, meaning its physicians have published more landmark research in this area than any other institution in the country. This research standing translates directly into clinical expertise: the surgeons are among the most experienced in D2 gastrectomy, the medical oncologists have the deepest familiarity with novel perioperative regimens, and the institution has access to clinical trials testing next-generation agents before they receive regulatory approval. For patients with gastric cancer, this depth of disease-specific experience is a meaningful clinical advantage.
What makes PKU Cancer Hospital's melanoma programme different for Asian patients?
Melanoma in Asian patients most commonly presents as acral lentiginous melanoma (on palms, soles, and under nails) or mucosal melanoma (nasal, oral, anorectal, or vaginal sites). These subtypes have distinct genetic profiles — high rates of KIT amplification or mutation and NF1 mutations, lower rates of BRAF V600E — compared to the UV-induced cutaneous melanoma predominant in Western populations. Most published clinical trial data and most Western treatment protocols are based on the UV-driven subtype. PKU Cancer Hospital's programme is specifically experienced with Asian-prevalent subtypes and the targeted therapy and immunotherapy regimens most appropriate for them, providing a fundamentally better fit for Asian patients than institutions applying Western protocols.
Do I need molecular profiling before seeking a consultation?
For gastric, colorectal, and melanoma cases, molecular profiling significantly improves the quality of the initial consultation. HER2 status, PD-L1 CPS score, MMR/MSI status, and NGS panel results allow the specialist to immediately assess treatment options, trial eligibility, and appropriate targeted therapy selection. PKU Cancer Hospital can perform its own molecular testing if profiling has not yet been done. Submit whatever reports you have — China Care will flag which additional tests may be needed. Consulting without profiling is possible; consulting with profiling is more productive.
Can international patients access clinical trials?
Yes, subject to individual trial eligibility criteria. PKU Cancer Hospital's immunotherapy and gastric cancer trial portfolios include studies open to international patients. Eligibility is based on tumour type, prior treatment history, molecular profile, and performance status. China Care identifies potentially relevant trials at case review stage; the hospital's clinical trials team completes a formal eligibility assessment during the initial consultation. Patients who qualify have access to novel agents and combinations not yet available in most countries.
How long do treatment stays typically last?
Duration varies by treatment type. Second opinion consultations can be completed in 3–5 days. Gastric surgery including preoperative investigations, surgery, and initial postoperative recovery typically requires 14–21 days of inpatient stay. Systemic therapy cycles are administered in outpatient cycles, typically 2–3 weeks apart, with patients returning home between cycles. For patients on clinical trials requiring regular monitoring visits, China Care assists with planning travel around the trial schedule.
What happens if my case is not suitable for PKU Cancer Hospital?
China Care conducts an honest case review before coordinating any referral. If your cancer type or clinical profile is better served by a different institution, we will say so and explain why. PKU Cancer Hospital is the strongest choice for gastric cancer, melanoma, immunotherapy access, and colorectal and gynaecological oncology. For haematological malignancies, rare cancers, or cases requiring radiation oncology as the primary treatment, we may recommend CAMS Cancer Hospital or another specialist institution. Our goal is the right referral, not the nearest one.
Get Started
Ready to enquire about treatment at PKU Cancer Hospital?
Submit your records through China Care and we will coordinate your case with PKU Cancer Hospital's oncology team, including a proxy consultation before you travel.
China Care coordinates your referral to PKU Cancer Hospital's international patient team. Treatment costs are quoted directly by the hospital. We never add to, inflate, or mark up the hospital's quoted treatment cost.
